- Home
- DCGO vs KRRO Comparison
DCGO vs KRRO Comparison
Compare DCGO & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCGO
- KRRO
- Stock Information
- Founded
- DCGO 2015
- KRRO 2014
- Country
- DCGO United States
- KRRO United States
- Employees
- DCGO N/A
- KRRO N/A
- Industry
- DCGO Managed Health Care
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- DCGO Health Care
- KRRO Health Care
- Exchange
- DCGO Nasdaq
- KRRO Nasdaq
- Market Cap
- DCGO 433.7M
- KRRO 490.1M
- IPO Year
- DCGO N/A
- KRRO 2019
- Fundamental
- Price
- DCGO $4.51
- KRRO $43.67
- Analyst Decision
- DCGO Strong Buy
- KRRO Strong Buy
- Analyst Count
- DCGO 5
- KRRO 7
- Target Price
- DCGO $6.10
- KRRO $133.83
- AVG Volume (30 Days)
- DCGO 734.1K
- KRRO 132.1K
- Earning Date
- DCGO 11-07-2024
- KRRO 11-12-2024
- Dividend Yield
- DCGO N/A
- KRRO N/A
- EPS Growth
- DCGO 300.38
- KRRO N/A
- EPS
- DCGO 0.29
- KRRO N/A
- Revenue
- DCGO $694,968,328.00
- KRRO N/A
- Revenue This Year
- DCGO $2.08
- KRRO N/A
- Revenue Next Year
- DCGO N/A
- KRRO N/A
- P/E Ratio
- DCGO $15.81
- KRRO N/A
- Revenue Growth
- DCGO 30.19
- KRRO N/A
- 52 Week Low
- DCGO $2.75
- KRRO $30.01
- 52 Week High
- DCGO $5.70
- KRRO $98.00
- Technical
- Relative Strength Index (RSI)
- DCGO 63.59
- KRRO 43.00
- Support Level
- DCGO $4.08
- KRRO $41.03
- Resistance Level
- DCGO $4.34
- KRRO $52.00
- Average True Range (ATR)
- DCGO 0.25
- KRRO 6.03
- MACD
- DCGO -0.00
- KRRO 0.03
- Stochastic Oscillator
- DCGO 78.57
- KRRO 42.36
About DCGO DocGo Inc.
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company has three reportable segments: Mobile Health Services, Transportation Services, and Corporate. Mobile Health Services is the key revenue-generating segment for the company.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.